Business Description
Sprint Bioscience AB
ISIN : SE0006343745
Total Employee Number:
30Compare
Compare
Traded in other countries / regions
SPRINT.Sweden5JA1.Germany IPO Date
2014-11-07Description
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.89 | |||||
Interest Coverage | 15.94 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 24.76 | |||||
Beneish M-Score | -1.86 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Book Growth Rate | 41.7 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.4 | |||||
9-Day RSI | 47.98 | |||||
14-Day RSI | 52.34 | |||||
3-1 Month Momentum % | 35.6 | |||||
6-1 Month Momentum % | 127.52 | |||||
12-1 Month Momentum % | 572.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.1 | |||||
Quick Ratio | 9.1 | |||||
Cash Ratio | 8.54 | |||||
Days Sales Outstanding | 0.29 | |||||
Days Payable | 141.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -14.1 | |||||
Shareholder Yield % | -3.93 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 93.83 | |||||
Operating Margin % | 57.49 | |||||
Net Margin % | 55.2 | |||||
EBITDA Margin % | 59.51 | |||||
FCF Margin % | 46.05 | |||||
OCF Margin % | 46.05 | |||||
ROE % | 169.33 | |||||
ROA % | 120.86 | |||||
ROIC % | 431.64 | |||||
ROC (Joel Greenblatt) % | 2269.12 | |||||
ROCE % | 180.4 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 5.21 | |||||
PE Ratio without NRI | 5.21 | |||||
Price-to-Owner-Earnings | 6.7 | |||||
PS Ratio | 2.76 | |||||
PB Ratio | 4.03 | |||||
Price-to-Tangible-Book | 4.02 | |||||
Price-to-Free-Cash-Flow | 6.28 | |||||
Price-to-Operating-Cash-Flow | 6.28 | |||||
EV-to-EBIT | 3.54 | |||||
EV-to-EBITDA | 3.52 | |||||
EV-to-Revenue | 2.09 | |||||
EV-to-FCF | 5.12 | |||||
Price-to-GF-Value | 1.86 | |||||
Price-to-Median-PS-Value | 0.67 | |||||
Price-to-Graham-Number | 0.97 | |||||
| Price-to-Net-Current-Asset-Value | 4.19 | |||||
| Price-to-Net-Cash | 4.46 | |||||
Earnings Yield (Greenblatt) % | 28.14 | |||||
FCF Yield % | 16.45 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sprint Bioscience AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 153.059 | ||
| EPS (TTM) (kr) | 0.78 | ||
| Beta | -0.465 | ||
| 3-Year Sharpe Ratio | 0.86 | ||
| 3-Year Sortino Ratio | 2.87 | ||
| Volatility % | 118.53 | ||
| 14-Day RSI | 52.34 | ||
| 14-Day ATR (kr) | 0.284006 | ||
| 20-Day SMA (kr) | 4.0445 | ||
| 12-1 Month Momentum % | 572.62 | ||
| 52-Week Range (kr) | 0.476 - 4.59 | ||
| Shares Outstanding (Mil) | 105.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sprint Bioscience AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sprint Bioscience AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-11 | In 131 days | ||
| Second quarter earnings results for 2026 | 2026-08-26 | In 54 days | ||
| General meeting for 2026 | 2026-05-13 15:00 | 3.66 (-5.67%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 3.66 (-5.67%) | ||
| Annual report for 2025 | 2026-04-15 | 4.04 (+6.32%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-11 | 1.87 (+1.36%) | ||
| Third quarter earnings results for 2025 | 2025-11-25 | 1.44 (-7.10%) | ||
| Second quarter earnings results for 2025 | 2025-08-27 | 0.59 (+3.16%) | ||
| First quarter earnings results for 2025 | 2025-05-27 | 0.45 (+3.95%) | ||
| General meeting for 2025 | 2025-05-07 15:00 | 0.56 (-6.67%) |
Show
Entries
Sprint Bioscience AB Frequently Asked Questions
What is Sprint Bioscience AB(OSTO:SPRINT)'s stock price today?
The current price of OSTO:SPRINT is kr4.06. The 52 week high of OSTO:SPRINT is kr4.59 and 52 week low is kr0.48.
When is next earnings date of Sprint Bioscience AB(OSTO:SPRINT)?
The next earnings date of Sprint Bioscience AB(OSTO:SPRINT) is 2026-08-26.
Does Sprint Bioscience AB(OSTO:SPRINT) pay dividends? If so, how much?
Sprint Bioscience AB(OSTO:SPRINT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Sprint Bioscience AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers